Credit Suisse’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-34,100
| Closed | -$321K | – | 4544 |
|
|
2020
Q3 | $321K | Buy |
34,100
+477
| +1% | +$4.53K | ﹤0.01% | 3622 |
|
|
2020
Q2 | $257K | Sell |
33,623
-42,017
| -56% | -$321K | ﹤0.01% | 3651 |
|
|
2020
Q1 | $467K | Sell |
75,640
-4,348
| -5% | -$38.3K | ﹤0.01% | 3158 |
|
|
2019
Q4 | $973K | Buy |
79,988
+45,741
| +134% | +$500K | ﹤0.01% | 3146 |
|
|
2019
Q3 | $395K | Buy |
34,247
+1,798
| +6% | +$18.9K | ﹤0.01% | 3573 |
|
|
2019
Q2 | $323K | Sell |
32,449
-233
| -0.7% | -$2.51K | ﹤0.01% | 3650 |
|
|
2019
Q1 | $421K | Sell |
32,682
-4,885
| -13% | -$72.7K | ﹤0.01% | 3429 |
|
|
2018
Q4 | $570K | Sell |
37,567
-4,881
| -11% | -$93K | ﹤0.01% | 3174 |
|
|
2018
Q3 | $849K | Buy |
42,448
+4,029
| +10% | +$91.7K | ﹤0.01% | 2980 |
|
|
2018
Q2 | $749K | Sell |
38,419
-4,291
| -10% | -$94.9K | ﹤0.01% | 3211 |
|
|
2018
Q1 | $861K | Buy |
42,710
+268
| +0.6% | +$4.53K | ﹤0.01% | 3056 |
|
|
2017
Q4 | $562K | Sell |
42,442
-8,306
| -16% | -$125K | ﹤0.01% | 3369 |
|
|
2017
Q3 | $936K | Sell |
50,748
-18,717
| -27% | -$349K | ﹤0.01% | 3152 |
|
|
2017
Q2 | $1.28M | Sell |
69,465
-75,977
| -52% | -$1.51M | ﹤0.01% | 2542 |
|
|
2017
Q1 | $3.28M | Buy |
145,442
+80,011
| +122% | +$1.92M | ﹤0.01% | 1964 |
|
|
2016
Q4 | $2.28M | Buy |
65,431
+17,139
| +35% | +$512K | ﹤0.01% | 2342 |
|
|
2016
Q3 | $1.18M | Buy |
48,292
+6,681
| +16% | +$167K | ﹤0.01% | 2819 |
|
|
2016
Q2 | $995K | Sell |
41,611
-5,846
| -12% | -$134K | ﹤0.01% | 2924 |
|
|
2016
Q1 | $1.11M | Buy |
47,457
+26,195
| +123% | +$622K | ﹤0.01% | 2644 |
|
|
2015
Q4 | $642K | Sell |
21,262
-55,713
| -72% | -$1.8M | ﹤0.01% | 3183 |
|
|
2015
Q3 | $3.06M | Sell |
76,975
-31,995
| -29% | -$1.99M | ﹤0.01% | 1952 |
|
|
2015
Q2 | $7.53M | Buy |
108,970
+50,590
| +87% | +$3.18M | 0.01% | 1437 |
|
|
2015
Q1 | $3.19M | Buy |
58,380
+9,798
| +20% | +$467K | ﹤0.01% | 2020 |
|
|
2014
Q4 | $2.07M | Buy |
48,582
+21,669
| +81% | +$783K | ﹤0.01% | 2504 |
|
|
2014
Q3 | $859K | Buy |
26,913
+4,052
| +18% | +$86.4K | ﹤0.01% | 3188 |
|
|
2014
Q2 | $474K | Sell |
22,861
-23,394
| -51% | -$432K | ﹤0.01% | 3862 |
|
|
2014
Q1 | $895K | Sell |
46,255
-31,445
| -40% | -$668K | ﹤0.01% | 3228 |
|
|
2013
Q4 | $1.89M | Buy |
77,700
+33,311
| +75% | +$783K | ﹤0.01% | 2700 |
|
|
2013
Q3 | $953K | Buy |
44,389
+19,233
| +76% | +$454K | ﹤0.01% | 2998 |
|
|
2013
Q2 | $560K | Buy |
+25,156
| New | +$554K | ﹤0.01% | 3229 |
|
Credit Suisse's AMAG Position: Q4 2020 in Review
Credit Suisse sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 34,100 shares — an estimated $321K sold.
Credit Suisse first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $7.53M in Q2 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Credit Suisse reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Credit Suisse sold 34,100 AMAG Pharmaceuticals shares in Q4 2020, an estimated $321K.
- Credit Suisse first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Credit Suisse's AMAG Pharmaceuticals position peaked at $7.53M in Q2 2015.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.